Verona Pharma Q1 2025 Results: Net Loss Reported
| Field | Detail |
|---|---|
| Company | Verona Pharma PLC |
| Form Type | 10-Q |
| Filed Date | Apr 29, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceutical, financials, quarterly-report
TL;DR
**Verona Pharma Q1 2025: Still burning cash, net loss continues.**
AI Summary
Verona Pharma plc reported its first quarter results for the period ending March 31, 2025. The company's financial statements indicate a net loss for the quarter. Key personnel mentioned include David Zaccardelli, President and CEO, and Andrew Fisher, General Counsel.
Why It Matters
This filing provides insight into Verona Pharma's financial performance and operational status in early 2025, which can influence investor decisions and market perception.
Risk Assessment
Risk Level: medium — The company reported a net loss, indicating ongoing operational expenses without sufficient revenue generation, which is a common risk for pharmaceutical development companies.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the first quarter for which financial results are reported.)
- 2025-01-01 — Reporting Period Start Date (Indicates the start of the first quarter for which financial results are reported.)
Key Players & Entities
- Verona Pharma plc (company) — Filer of the 10-Q report
- David Zaccardelli (person) — President and Chief Executive Officer
- Andrew Fisher (person) — General Counsel
- Christina Ackermann (person) — Non-Executive Director
FAQ
What was Verona Pharma's net income or loss for the first quarter of 2025?
The filing indicates a net loss for the period from January 1, 2025, to March 31, 2025, though specific dollar amounts for net income/loss are not detailed in this excerpt.
What is the company's primary business segment?
The company's business is primarily related to 'Product' and 'ProductAndServiceOther' segments, as indicated by the XBRL tags.
When was this 10-Q filing submitted?
This 10-Q filing was submitted on April 29, 2025.
Who are the key executive officers mentioned in the filing?
Key executives mentioned include David Zaccardelli (President and Chief Executive Officer) and Andrew Fisher (General Counsel).
What is Verona Pharma's fiscal year end?
Verona Pharma's fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on April 29, 2025 by David Zaccardelli regarding Verona Pharma plc.